Paravasthu Mukund's Form 4 filing
NovoCure Ltd (NVCR) · filed Mar 3, 2025
- Accession no.
- 0001562180-25-001831
- Filed
- Mar 3, 2025
- Trade date
- Feb 27-28, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market sales total $39.7K. It was filed 4 days after the trade.
This filing was later replaced by the amendment 0001562180-25-001912 (Mar 3, 2025). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Paravasthu MukundCIK 0002039078 | Officer (Chief Operating Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 27, 2025 | Ordinary Shares | SSaleDisposed | −1,379 | $19.92F1 | −$27,469.68 | 30,058 | Direct | |
| Feb 27, 2025 | Ordinary Shares | SSaleDisposed | −267 | $20.55F2 | −$5,486.85 | 29,791 | Direct | |
| Feb 28, 2025 | Ordinary Shares | SSaleDisposed | −368 | $18.28F3 | −$6,727.04 | 29,423 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On February 27, 2025, the reporting person sold 1,379 shares in multiple trades at prices ranging from $19.41 to $20.4033. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F2
On February 27, 2025, the reporting person sold 267 shares in multiple trades at prices ranging from $20.41 to $20.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F3
On February 28, 2025, the reporting person sold 368 shares in multiple trades at prices ranging from $18.175 to $18.765. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.